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Isoprenylation of RhoB Is Necessary for Its Degradation
A NOVEL DETERMINANT IN THE COMPLEX REGULATION OF RhoB EXPRESSION BY THE
MEVALONATE PATHWAY*
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Statins improve vascular functions by mechanisms in-
dependent from their cholesterol-lowering effect. Rho
GTPases are emerging as key targets for the vascular
effects of statins. RhoB is a short-lived, early-response
inducible protein involved in receptor endocytosis, apo-
ptosis, and gene expression. Here we show that statins
regulate RhoB expression by acting at multiple levels.
Simvastatin increased RhoB protein levels by 8- to 10-
fold. This effect was related to a depletion of isoprenoid
intermediates, as deduced from the observation that
several metabolites of the cholesterol biosynthetic path-
way, namely, mevalonate and geranylgeranyl-pyrophos-
phate, attenuated simvastatin-induced RhoB up-regula-
tion. Moreover, prenyltransferase inhibitors mimicked
simvastatin effect. Cholesterol supplementation did not
prevent simvastatin-elicited up-regulation but in-
creased RhoB levels per se. Simvastatin moderately aug-
mented RhoB transcript levels, but markedly impaired
the degradation of RhoB protein, which accumulated in
the cytosol in its non-isoprenylated form. Inhibition of
RhoB isoprenylation was apparently required for simv-
astatin-induced up-regulation, because levels of an iso-
prenylation-deficient RhoB mutant were not affected by
simvastatin. Moreover, this mutant was found to be
markedly more stable than the wild-type protein. These
results show that RhoB isoprenylation is necessary for
rapid turnover of this protein and identify a novel link
between the cholesterol biosynthetic pathway and the
regulation of G-protein expression.
Statins are a family of drugs widely used in the treatment of
hypercholesterolemia. They are competitive inhibitors of hy-
droxymethylglutaryl-CoA (HMG-CoA)1 reductase (1), the en-
zyme catalyzing the rate-limiting step in the synthesis of cho-
lesterol, that is, the conversion of HMG-CoA to mevalonate
(Scheme 1). Mevalonate is also the precursor of farnesyl-pyro-
phosphate and geranylgeranyl-pyrophosphate, the isoprenoid
lipids involved in the posttranslational modification of a num-
ber of proteins, including most G-proteins (2, 3). For this
reason, statins have also been used as pharmacological tools
to assess the importance of protein isoprenylation in signal
transduction (4, 5).
The clinical use of statins has revealed that these drugs
promote beneficial effects on cardiovascular functions that do
not correlate with their ability to lower serum cholesterol levels
(6, 7). Treatment of endothelial cells with statins increases or
preserves the expression of endothelial nitric oxide synthase (8,
9), while inhibiting the production of endothelin-1 (10). In
addition, antiproliferative and anti-inflammatory effects of
statins have been observed in several experimental systems (5,
11–13) and in patients (14, 15). Elucidation of the mechanisms
underlying these diverse effects has shown that small G-pro-
teins of the Rho family are critical targets for statins in many
systems. Rho GTPases participate in the regulation of numer-
ous cellular functions, including cytoskeletal organization, cell
adhesion, smooth muscle contraction, endocytosis, receptor sig-
naling, cell cycle progression, and gene expression (16–19). Rho
proteins are posttranslationally modified by isoprenylation at a
cysteine residue located near their C-terminal end (20). Inhi-
bition of Rho function by impairment of protein isoprenylation
is at the basis of the reported effects of statins on smooth
muscle cell proliferation (11), endothelial nitric oxide synthase
and inducible nitric oxide synthase expression (8, 21), pre-pro-
endothelin-1 transcription (10), and protection against cerebral
stroke (22). Evidence accumulating during the last decade in-
dicates that, by limiting mevalonate availability, statins may
influence not only the function but also the expression of sev-
eral G-proteins, including Ras (23), Rab (24), Rap (25), and Rho
proteins (26–28). However, the mechanisms responsible for
these effects are not fully elucidated.
RhoB is a short-lived protein, the levels of which can be
regulated by growth factors and stress signals both transcrip-
tionally and posttranslationally (26, 29). RhoB can be modified
either by farnesylation or geranylgeranylation at its C termi-
nus (20), and it has been proposed that its function may depend
on the presence and the nature of the isoprenoid moiety (30).
Among the reported RhoB functions are the modulation of
receptor endocytosis (31), apoptosis (32), and vascular gene
expression, including that of pre-pro-endothelin-1 (10) and in-
ducible nitric oxide synthase (33). A detailed knowledge of the
effect of statins on Rho protein biology is of primary importance
in the context of the therapeutic strategies for hypercholester-
olemia and atherosclerosis. In the present study we have ex-
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plored the effect of statins on RhoB expression and processing
in several cell types. Our results show that statins drastically
increase the levels of cellular RhoB by mechanisms that involve
the regulation of RhoB mRNA by the cholesterol biosynthetic
pathway and the impairment of the proteolytic degradation of
the non-isoprenylated RhoB protein. This latter observation
provides the first evidence for the regulation of protein stability
by isoprenylation.
MATERIALS AND METHODS
Materials—Simvastatin, lovastatin, and zaragocic acid were from
Merck Sharp and Dohme. Antibodies anti-RhoA (sc-418), anti-RhoB
(sc-180), and anti-HA (sc-7392) were from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti-pan-Ras-10 (Ab-3) monoclonal antibody was
from Oncogene Science (Uniondale, NY). Peroxidase-conjugated anti-
rabbit and anti-mouse immunoglobulins were from Dako (Glostrup,
Denmark). Deoxycytidine 5-triphosphate [-32P]- (3,000 Ci/mmol) was
from Amersham, Aylesbury, UK. FTI-277, GGTI-286, toxin B from
Clostridium difficile, C3 exoenzyme from Clostridium botulinum, and
the Rho-associated kinase inhibitor Y-27632 were from Calbiochem-
Novabiochem (San Diego, CA). All other reagents were of the highest
purity available from Sigma.
Cell Culture—Bovine aortic endothelial cells (BAEC) were isolated
from thoracic aortas and characterized as previously described (9). Cells
were maintained in RPMI 1640 supplemented with 10% calf serum, 2
mM glutamine, 100 units/ml penicillin and 100 g/ml streptomycin in
an atmosphere with 5% CO2. Experiments were performed on confluent
monolayers at passages 3–8 made quiescent by serum deprivation for
24 h. Potential toxicity of the reagents used was tested by trypan blue
exclusion and by analysis of the cell cycle distribution by flow cytometry
(34). The concentrations of simvastatin used throughout this study did
not induce apoptosis in BAEC. Mesangial cells were obtained and
characterized as reported previously (35). Human umbilical vein endo-
thelial cells were isolated and cultured according to published proce-
dures (36). Mv1Lu, HeLa, and NIH-3T3 cells were from the Animal Cell
Culture facility of Centro de Investigaciones Biolo´gicas. Mv1Lu and
NIH-3T3 cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, and HeLa cells were cul-
tured in RPMI 1640 plus 10% fetal bovine serum.
SDS-PAGE and Immunoblotting—For SDS-PAGE, BAEC were ho-
mogenized by forced passes through a 261⁄2-gauge needle in 10 mM Tris,
pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.5% SDS, 0.1 mM -mercapto-
ethanol, containing 2 g/ml of each of the protease inhibitors leupeptin,
aprotinin, and pepstatin. Protein was measured by the BCA method
(Pierce, Rockford, IL), and aliquots containing 20 g of protein were
electrophoresed on 15% SDS-polyacrylamide gels and transferred to
Immobilon-P membranes (Millipore, Bedford, MA). Blots were incu-
bated with anti-RhoA (1:1,000), anti-RhoB (1:500), or anti-pan-Ras
(1:1,000) antibodies, and the proteins of interest were visualized using
an ECL detection system from Amersham Biosciences. Levels of RhoA
and B proteins were estimated by image scanning of the ECL expo-
sures. The values obtained were corrected by the band intensities of the
Coomassie staining of membranes after the blotting procedure or by the
signal given by an antibody against a non-related protein.
Subcellular Fractionation—For obtention of S100 (cytosol) and P100
(membrane) fractions, cells were homogenized in 20 mM Tris, pH 7.5, 5
mM MgCl2, 1 mM EDTA, 250 mM sucrose, and 0.1 mM dithiothreitol
containing protease inhibitors, and lysates were centrifuged at
200,000  g for 30 min at 4 °C in a Beckman TLA100 rotor.
Determination of RhoB Protein Stability—For this purpose, a previ-
ously published method was used (26). After treatment in the absence
or presence of simvastatin, cells were incubated with 20 g/ml cyclo-
heximide, a concentration that effectively blocked synthesis of RhoB
protein, and levels of RhoB were analyzed by Western blot at various
time points after cycloheximide addition.
RNA Isolation, Northern Blotting, and Hybridization—Total cellular
RNA was isolated from BAEC with the guanidinium thiocyanate-phe-
nol-chloroform method and processed as previously reported (10). Equal
loading was ensured by ethidium bromide staining. For analysis of
RhoB mRNA expression, the full-length rat RhoB cDNA, a gift of Dr.
G. C. Prendergast (The Wistar Institute, Philadelphia, PA), was used as
a probe. Blots were stripped and rehybridized with a probe for human
-actin. Densitometric analysis was performed using an Agfa Stu-
dioStar TPO scanner with the public domain software NIH IMAGE
1.60b5. Results were calculated as the ratio of RhoB/-actin mRNA
levels.
Plasmids and Transfections—The mammalian expression vector en-
coding the rat RhoB cDNA tagged at the amino terminus with a he-
magglutinin epitope (pcDNA3-HA-RhoB) was generously provided by
Dr. G.C. Prendergast. The isoprenylation-deficient HA-RhoBC193S
mutant was generated from the above plasmid by PCR using primers
forward: 5-CCAGAGAGATCTATGTACCCATACGATGTGCCAGAC-3
and reverse: 3-CAGAGCTCTAGATCATAGCACCTTCGAGCAGTTGA-
TG-5. The DNA fragments encoding wild-type and mutant HA-RhoB
were subcloned into the BglII, EcoRI sites of the pEGFP-C1 vector
(Clontech). Cells grown on 6-well plates or on 12-mm glass coverslips
were transfected using LipofectAMINE Plus reagent (Invitrogen) fol-
SCHEME 1. Main intermediates in
the cholesterol/isoprenoid biosyn-
thetic pathway and pharmacological
tools used to explore it. Enzymes of
this pathway are represented in shaded
rectangles and the corresponding inhibi-
tors in arrowheads. FTase, farnesyltrans-
ferase; GGTase, geranylgeranyltrans-
ferase; ZGA, zaragocic acid; LDL, low
density lipoproteins.
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lowing the instructions of the manufacturer. After a 24-h recovery
period, cells were exposed to the various agents. The expression of RhoB
or of GFP-RhoB proteins was monitored by Western blot or confocal
fluorescence microscopy, as indicated. Transfection efficiency was
80% in NIH-3T3 cells as estimated from fluorescence microspcopy
analysis of GFP-RhoB transfected cells.
RESULTS
HMG-CoA Inhibitors Increase RhoB Protein Levels in Vascu-
lar Endothelial Cells—Treatment of quiescent BAEC with the
HMG-CoA inhibitor simvastatin led to a time- and dose-de-
pendent increase in RhoB protein levels (Fig. 1). An increase in
RhoB could be detected after a 24-h treatment with 0.1–1 M
simvastatin, a concentration in the range of that reached in the
plasma of patients treated with this drug (37), although the
effect was more evident at simvastatin concentrations above 1
M, which are higher than those seen in humans. Treatment of
BAEC with 10 M simvastatin for 24 h resulted in 6- to 10-fold
higher RhoB protein levels. RhoA protein was also more abun-
dant after simvastatin treatment (2- to 3-fold increase). The
levels of Ras proteins, detected with a pan-Ras antibody, did
not change appreciably under these experimental conditions. A
similar effect on RhoB protein levels was brought about by
other HMG-CoA reductase inhibitors, namely, lovastatin and
compactin (Fig. 1C). This phenomenon was not restricted to
BAEC, because it could also be evidenced in human umbilical
vein endothelial cells and mesangial cells treated with simvas-
tatin (Fig. 2). Simvastatin induced an increase in RhoB levels
in all the cell types thus far studied, including 293T and COS-7
cells (data not shown), the epithelial cell lines Mv1Lu and
HeLa, and in NIH-3T3 fibroblasts (Fig. 2).
Regulation of RhoB Expression by the Mevalonate Pathway—
Statins are potent cholesterol-lowering agents. Therefore we
explored whether the effect of simvastatin could be prevented
by increasing cholesterol supply. Cholesterol supplementation
did not prevent simvastatin-induced RhoB up-regulation in
BAEC (Fig. 3A, left); conversely, a moderate up-regulation of
RhoB protein levels could be detected in cholesterol-supple-
mented cells (1.6  0.12-fold increase with respect to control
levels, n  4). Because both simvastatin and cholesterol reduce
the flux through the cholesterol biosynthetic pathway, these
observations suggest that a down-regulation of this pathway or
the depletion of some intermediate(s) may be involved in the
effect of simvastatin. In keeping with this, treatment of BAEC
with zaragocic acid, an inhibitor of squalene synthase, expected
to increase the activity of the pathway (38), moderately reduced
RhoB protein levels (20–30% reduction, n  3, not shown).
Incubation of BAEC in the presence of mevalonate attenuated
the up-regulation of RhoB levels by simvastatin (Fig. 3A, right).
To ascertain whether this effect was dependent on some spe-
cific products of mevalonate we explored the ability of various
isoprenoid intermediates to circumvent simvastatin-induced
up-regulation of RhoB (Fig. 3A, right). Incubation of BAEC
with farnesyl-pyrophosphate during treatment with simvasta-
tin slightly reduced the up-regulation of RhoB protein levels
whereas geranylgeranyl-pyrophosphate (GGPP) had a protec-
tive effect similar to that of mevalonate. This effect of GGPP
was not restricted to BAEC because it was also observed in
HeLa and NIH-3T3 cells (results not shown).
The RhoB protein and transcript are short-lived species, the
levels of which can be modulated both transcriptionally and
posttranscriptionally (26, 29). To get insight into the mecha-
nism of simvastatin-induced RhoB up-regulation we explored
the levels of RhoB mRNA. As it can be observed in Fig. 3B
simvastatin augmented the levels of RhoB transcript by 2-
fold, an extent lower than that observed at the protein level.
The effect of simvastatin was specific for RhoB as evidenced by
the observation that the levels of -actin did not increase or
were slightly decreased by simvastatin treatment. Cholesterol
supplementation did not increase RhoB mRNA levels apprecia-
bly and was also ineffective at preventing the effect of simvas-
tatin. RhoB mRNA levels followed a pattern similar to that
observed for the RhoB protein in response to supplementation
with mevalonate, farnesyl-pyrophosphate, and GGPP (Fig. 3B,
right). The ability of GGPP to prevent simvastatin-induced
RhoB up-regulation suggested the involvement of geranylgera-
nylated proteins in this effect. Because most G-proteins are
modified by geranylgeranylation, we took advantage of the
availability of bacterial toxins that selectively inactivate spe-
cific types of G-proteins to assess their effect on RhoB levels
(Fig. 4). Treatment of BAEC with pertussis toxin, which inhib-
FIG. 1. Effect of HMG-CoA inhibitors on the abundance of
RhoB protein in BAEC. A, BAEC were treated with simvastatin (Sv)
at 10 M for the indicated time periods, and the levels of RhoB, RhoA,
and Ras proteins were assessed by immunoblot. B, BAEC were treated
with the indicated concentrations of simvastatin or (C) with different
HMG-CoA inhibitors at 10 M for 24 h. Results shown are representa-
tive of at least three experiments. Lov, lovastatin; Comp, compactin.
FIG. 2. Effect of simvastatin on RhoB protein levels in several
cell types. The indicated cell types were treated with simvastatin for
24 h. HUVEC, human umbilical vein endothelial cells; MC, glomerular
mesangial cells; Mv1Lu, mink lung epithelial cells; HeLa, epitheloid
carcinoma cells; NIH-3T3, mouse fibroblasts. RhoB levels were as-
sessed by Western blot. Results shown are representative of at least two
experiments.
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its Gi proteins, or with cholera toxin, which stimulates Gs
proteins did not alter RhoB protein levels significantly (Fig.
4A). In contrast, treatment with either toxin B from Clostrid-
ium difficile, or with Clostridium botulinum C3 exoenzyme,
known to block the activity of Rho proteins, increased RhoB
levels, although to a lesser extent than simvastatin (Fig. 4B).
Moreover, the Rho kinase inhibitor Y-27632 also augmented
RhoB protein levels moderately. Interestingly, both toxin B and
Y-27632 induced a similar increase in RhoB mRNA levels (Fig.
4C). Taken together, these observations suggest that the in-
crease in RhoB mRNA expression induced by simvastatin could
be mediated by the impairment geranylgeranylated proteins,
among which Rho proteins are good candidates. However, the
higher extent of amplification of RhoB protein levels by simv-
astatin suggests that there may be translational or posttrans-
lational mechanisms that contribute to this effect.
Effect of Simvastatin on RhoB Protein Stability—RhoB pro-
tein degradation is an important process for the control of RhoB
protein levels (26). We then explored whether this process was
affected by simvastatin. In control cells, inhibition of protein
synthesis with cycloheximide lead to a rapid decrease in RhoB
protein levels, with less than 50% RhoB protein remaining
after 6 h (Fig. 5A). In contrast, in cells pre-treated with sim-
vastatin for 24 h, the decay of RhoB protein levels was signif-
icantly reduced, thus suggesting the contribution of posttrans-
lational events to simvastatin-elicited RhoB up-regulation.
Treatment with simvastatin at the time of cycloheximide ad-
dition did not result in increased RhoB levels (Fig. 5B). Also, in
these co-treatment experiments, the decay of RhoB levels was
not reduced, even when a concentration of 40 M simvastatin
was used (n  2, results not shown), thus making unlikely the
possibility of a direct interference of simvastatin with the ac-
tivity of cellular proteases.
Effect of Simvastatin on RhoB Subcellular Distribution and
Processing—Decreased degradation of RhoB in simvastatin-
treated cells could result from alterations in RhoB subcellular
localization and/or function due to impaired posttranslational
processing. To test this hypothesis we assessed the effect of
simvastatin on RhoB subcellular distribution and processing.
In confluent, serum-deprived BAEC, RhoB was predominantly
membrane-bound (Fig. 6A). In simvastatin-treated cells, the
amount of membrane-bound RhoB was significantly reduced,
whereas the increase in RhoB protein was exclusively localized
to the soluble fraction. Treatment with simvastatin also led to
a decrease in the electrophoretic mobility of RhoB protein,
which is indicative of the lack of posttranslational modification
FIG. 3. Effect of cholesterol availability and isoprenoid intermediates on RhoB protein and mRNA abundance. A, BAEC were
incubated with the indicated agents for 24 h and RhoB protein levels were estimated by immunoblot. Sv, 10 M simvastatin; Chol, 100 g/ml
cholesterol; Mv, 100 M mevalonic acid; FPP, 5 M farnesyl-pyrophosphate; GGPP, 5 M geranylgeranyl-pyrophosphate. Levels of RhoB protein
estimated by image scanning of ECL exposures, expressed in arbitrary units, are shown at the bottom. Results are representative of at least three
experiments. B, BAEC were treated with the indicated agents as above. RhoB mRNA levels were determined by Northern blot. Blots were
hybridized first with RhoB cDNA and reprobed with -actin cDNA. Lower panels depict the densitometric analysis of RhoB mRNA levels after
correction by the expression of -actin. Data are mean  S.E. of three independent experiments. *, p  0.05 versus simvastatin by Student’s t test.
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(26) (Fig. 6B). Thus, in simvastatin-treated cells, most of RhoB
protein is accumulated in the cytosol in its non-isoprenylated
form.
RhoB Isoprenylation Is Necessary for Degradation—To ascer-
tain whether the effect of simvastatin was related to the inhi-
bition of protein isoprenylation we first explored the ability of
the inhibitors of protein farnesyltransferase and geranylgera-
nyltransferase I, FTI-277 and GGTI-286, respectively, to in-
crease RhoB levels (Fig. 7A). We observed that FTI-277 slightly
increased the levels of RhoB protein and GGTI-286 induced a
3.8-fold increase of RhoB expression in BAEC (n  4). The
combination of the two inhibitors induced a potent increase in
RhoB protein levels, that was comparable with that attained
with simvastatin (8-fold increase, average of four experiments).
A similar effect of prenyltransferase inhibitors was observed in
NIH-3T3 fibroblasts (Fig 7A). We next evaluated whether non-
isoprenylated, cytosolic RhoB displays increased stability with
respect to the wild-type protein. For this purpose, we generated
wild-type and isoprenylation-deficient RhoB constructs and as-
sessed their subcellular localization and stability in transient
transfection experiments (Fig. 7B). GFP-HA-RhoBwt showed a
preferential perinuclear distribution when transfected in NIH-
3T3 fibroblasts, with a particulate pattern indicative of mem-
brane association. In contrast, GFP-HA-RhoB-C193S showed a
diffuse distribution, indistinguishable from that of GFP (data
not shown), typical of soluble proteins. Treatment of GFP-HA-
RhoBwt-transfected fibroblasts with simvastatin caused a re-
distribution of RhoB from the membrane-associated to the sol-
uble compartment. We next explored the effect of simvastatin
on the expression of transiently transfected wild-type and mu-
tant RhoB proteins by Western blot and detection with an
anti-HA antibody (Fig. 7C). Simvastatin potently increased the
levels of HA-RhoBwt, suggesting that its effect largely depends
on the RhoB coding sequence. The levels of HA-RhoB-C193S
expressed in cells were consistently higher than those of HA-
RhoBwt and were not further increased by simvastatin, sug-
gesting that inhibition of RhoB isoprenylation is required for
simvastatin effect. Finally, we estimated the half-life of both
proteins. As shown in Fig. 7D, HA-RhoBwt levels decayed
rapidly upon inhibition of protein synthesis, displaying a sta-
bility similar to that of endogenous RhoB (Fig. 5). In contrast,
HA-RhoB-C193S was markedly more stable. These results
show that RhoB isoprenylation is required for rapid turnover of
this protein.
DISCUSSION
The results presented in this work show that RhoB levels are
modulated by the cholesterol biosynthetic pathway. Down-reg-
ulation of this pathway either by means of HMG-CoA reductase
inhibitors or excess cholesterol is associated with an increase in
the amount of RhoB. This regulation occurs in part at the
mRNA level and largely at the protein level, because inhibition
of RhoB isoprenylation either by pharmacological or genetic
manipulation markedly reduces the degradation of this
protein.
The cholesterol biosynthetic pathway provides the isopre-
noid intermediates needed for the posttranslational modifica-
tion of G-proteins. Although protein isoprenylation is an irre-
versible modification, it is susceptible to a certain degree of
regulation, because the activity of the prenyltransferases may
be controlled by some growth factors and by the availability of
isoprenoids. The cholesterol pathway is subjected to a complex
feedback regulation (1), and it can be modulated by stress (39).
In recent years it has become evident that the activity of this
pathway may control the maturation of certain G-proteins such
as Ras, thus resulting in the regulation of Ras-mediated cellu-
FIG. 4. Effect of bacterial toxins on RhoB levels. BAEC were treated with the indicated agents for 24 h, and the levels of RhoB protein and
mRNA were assessed by Western (A and B) or Northern blot (C). PTX, 0.5 g/ml pertussis toxin; CTX, 0.5 g/ml cholera toxin; ToxB, 0.5 ng/ml
toxin B from Clostridium difficile; C3, 50 g/ml Clostridium botulinum C3 exoenzyme; Y-27632, 5 M Rho-associated kinase inhibitor, Sv, 10 M
simvastatin Results shown are representative of at least three experiments. Levels of RhoB protein and mRNA estimated as in Fig. 3 are expressed
in arbitrary units. *, p  0.05 versus simvastatin by Student’s t test.
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lar processes in response to cholesterol levels or cellular stress
(39, 40). In addition, several lines of evidence indicate that the
mevalonate pathway may influence the expression of other
members of the Ras superfamily, namely Ras1 and Ras2 in
yeast (23), and Rab5 and Rab7 in thyroid cells (24), through
mechanisms not yet completely elucidated.
The relationship between G-protein expression and choles-
terol metabolism may be bidirectional. In a recent report, cdc42
proteins have been involved in the regulation of cholesterol
efflux (41). In addition, in fibroblasts from patients with the
inherited disorder of lipid metabolism known as Tangier dis-
ease, characterized by cellular accumulation of cholesteryl es-
ters, the expression of several Rho proteins, including RhoB, is
increased (42). On this basis, a role for Rho proteins in choles-
terol transport has been hypothesized. Our results raise the
possibility that the observed increase in Rho proteins expres-
sion may be caused in part by the accumulation of cholesterol
in cells.
The mechanisms by which the mevalonate pathway regu-
lates RhoB appear to be multiple. Recently, mevalonate deple-
tion has been reported to result in an increase in RhoB mRNA
(25). However, the involvement of isoprenoid intermediates or
isoprenylated proteins in this effect has not been explored.
Here we have shown that inhibition of mevalonate biosynthesis
with simvastatin moderately up-regulates RhoB mRNA levels
and that this effect is prevented by GGPP. In addition, we have
observed that inhibition of Rho signaling by means of bacterial
toxins that target and inactivate Rho proteins (43) or by a Rho
kinase inhibitor, is also associated with a moderate increase in
RhoB protein and mRNA levels. These observations suggest
that geranylgeranylated proteins and, in particular, Rho pro-
teins, exert a negative feedback on RhoB mRNA expression in
endothelial cells. This interpretation is in accordance with pre-
vious studies that identified a negative role of RhoA and B on
the activity of the mouse RhoB promoter (29). Our results
indicate that the main effect of simvastatin on RhoB expression
takes place at a posttranslational level by reducing RhoB deg-
radation. This could occur through several mechanisms. Sim-
vastatin could affect the activity of proteolytic pathways within
the cell. In fact, statins have been reported to modulate the
activity of the proteasome (44, 45), a protein-degradation path-
way proposed to mediate RhoB turnover (26). However, the
effect of simvastatin on RhoB levels and stability was com-
pletely prevented by co-treatment with cycloheximide, thus
showing that de novo protein synthesis is required for its effect.
Moreover, inhibition of protein isoprenylation by using peptido-
mimetic inhibitors of prenyltransferases reproduced the effect
of simvastatin on RhoB levels. These observations suggest that
the effect of simvastatin is related to the inhibition of protein
isoprenylation rather than to a direct interference with cellular
proteases. Because the increase in RhoB protein elicited by
simvastatin occurs at the expense of non-prenylated cytosol-
partitioned RhoB, it could be hypothesized that the immature
cytosolic protein is a poorer substrate for proteases or it does
not localize to the appropriate cellular compartment for degra-
dation. This is supported by the fact that the Cys193Ser RhoB
mutant, which lacks the isoprenylation site and is cytosolic, is
markedly more stable than the wild-type protein. These obser-
vations indicate that isoprenylation of RhoB determines the
half-life of the protein. Interestingly, carboxyl methylation of
the isoprenylated cysteine in RhoA has been reported to reduce
its turnover (46), thus providing another example of the regu-
FIG. 5. Effect of simvastatin on RhoB protein degradation. A,
BAEC were treated in the absence (Ct) or presence of 10 M simvastatin
(Sv), as indicated. After 24 h, protein synthesis was blocked by addition
of 20 g/ml cycloheximide, and RhoB protein levels were estimated by
immunoblot at several time points after cycloheximide addition. ECL
exposures shown correspond to a 4-min exposure for Ct and a 30-s
exposure for Sv. Results shown in the lower panel are average values 
S.E. of three experiments. B, BAEC were treated in the absence (Ct) or
presence of 10 M simvastatin and/or 20 g/ml cycloheximide (CHX) for
24 h, and levels of RhoB were assessed by immunoblot.
FIG. 6. Effect of simvastatin on RhoB subcellular localization
and processing. BAEC were incubated in the absence or presence of
10 M simvastatin for 24 h. A, S100 (cytosol) and P100 (membrane)
fractions were obtained and 10 g from each fraction were analyzed by
immunoblot. B, electrophoretic mobility of RhoB protein present in cell
lysates from control (20 g of total protein/lane) or simvastatin-treated
cells (4 g/lane) was assessed by immunoblot. A lower amount of pro-
tein was analyzed in the case of simvastatin-treated cells to avoid the
lack of resolution caused by RhoB overexpression. Results are repre-
sentative of at least three experiments.
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lation of Rho protein stability as a function of their posttrans-
lational processing.
Whether the increased stability of unprenylated RhoB is
caused by changes in subcellular distribution, activity, or abil-
ity to interact with other cellular proteins will be the subject of
further studies. Although inhibition of RhoB isoprenylation
may abolish some of RhoB functions, like its cell transforming
ability (47) or the activation of the endothelin-1 promoter (10),
other functions could be conserved, as it has been described for
the activation of the serum-response element-dependent tran-
scription in overexpression experiments (47). Future work will
address whether unprenylated RhoB may have specific func-
tions or whether it behaves as a dominant-negative RhoB
protein.
In conclusion, we have found that RhoB mRNA levels and
protein stability can be regulated by the availability of isopre-
noid intermediates needed for protein modification. These find-
ings unveil the novel role of isoprenylation in the control of
RhoB protein degradation and may contribute to the under-
standing of the complex structure-function relationships of
RhoB posttranslational modifications.
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